Trial Profile

A Phase 1b Study to Evaluate PF-05251749 for the Treatment of Sundowning in Alzheimer's Disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson's Disease (PD)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jan 2020 New trial record
13 Jan 2020 According to a Biogen media release, Biogen announced an agreement to acquire a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (PF-05251749) from Pfizer, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases.In particular, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimers disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinsons disease (PD).
13 Jan 2020 According to a Biogen media release, Biogen aims to initiate this Phase 1b study in Q4 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com